FY2017 EPS Estimates for Alnylam Pharmaceuticals, Inc. (ALNY) Lifted by Analyst

Adjust Comment Print

About 206,230 shares traded. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has risen 33.54% since February 8, 2017 and is uptrending. It has outperformed by 16.84% the S&P500.

Moses increased its stake in Cornerstone Ondemand Inc (CSOD) by 18.45% based on its latest 2017Q3 regulatory filing with the SEC. Tocqueville Asset Management L.P. now owns 20,775 shares of the biopharmaceutical company's stock worth $2,441,000 after purchasing an additional 4,200 shares in the last quarter. The Perceptive Advisors Llc holds 1.79 million shares with $210.17M value, down from 1.83M last quarter. Train Babcock Advisors Llc who had been investing in Wabtec Corp. for a number of months, seems to be bullish on the $6.99 billion market cap company. The regular trading started at $127.77 but as the trading progressed, the stock receded, completing the session with a decline of -3.81%. It has underperformed by 9.31% the S&P500.

Among 16 analysts covering Education Realty Trust (NYSE:EDR), 5 have Buy rating, 2 Sell and 9 Hold. Therefore 74% are positive. Alnylam Pharmaceuticals had 92 analyst reports since August 7, 2015 according to SRatingsIntel. Needham maintained Alnylam Pharmaceuticals, Inc. The stock has "Buy" rating by Ladenburg Thalmann on Thursday, February 2. The stock has a market capitalization of $12,242.19, a P/E ratio of -23.71 and a beta of 2.69. The company was maintained on Tuesday, July 11 by Credit Suisse. Finally, Gulf International Bank UK Ltd purchased a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter worth $3,792,000. The firm earned "Buy" rating on Thursday, September 21 by Cowen & Co. Chardan Capital Markets maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) rating on Sunday, January 7. The stock has "Buy" rating by Piper Jaffray on Thursday, November 2. The firm earned "Outperform" rating on Thursday, October 6 by FBR Capital. The company was maintained on Thursday, November 9 by Barclays Capital. BidaskClub raised shares of Alnylam Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, August 5th. The rating was maintained by Piper Jaffray on Friday, December 15 with "Buy".

Broadfin Capital Llc, which manages about $1.26B and $676.01 million US Long portfolio, upped its stake in Angiodynamics Inc (NASDAQ:ANGO) by 87,688 shares to 1.77M shares, valued at $30.27 million in 2017Q3, according to the filing.

Since September 20, 2017, it had 0 insider buys, and 3 insider sales for $23.18 million activity. On Thursday, January 4 the insider Mason Michael sold $4.84M.

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company.

EU's Barnier warns Britain post-Brexit transition 'not a given'
A United Kingdom decision to leave the single market and to leave the customs union would make border checks unavoidable'. Barnier said Britain has to accept the "consequences" of its decisions.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Wednesday, August 9th. After having $-1.34 EPS previously, Alnylam Pharmaceuticals, Inc.'s analysts see 4.48 % EPS growth.

Leerink Swann also issued estimates for Alnylam Pharmaceuticals' Q4 2017 earnings at ($1.35) EPS, Q1 2018 earnings at ($1.44) EPS, Q2 2018 earnings at ($1.53) EPS, Q3 2018 earnings at ($1.56) EPS, Q4 2018 earnings at ($1.46) EPS, FY2018 earnings at ($5.99) EPS and FY2019 earnings at ($5.38) EPS. It fall, as 30 investors sold Alnylam Pharmaceuticals, Inc. shares while 73 reduced holdings. 40 funds opened positions while 55 raised stakes. Emerald Advisers Pa reported 15,793 shares. Loring Wolcott Coolidge Fiduciary Ltd Liability Partnership Ma accumulated 8,275 shares or 0.02% of the stock.

Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 122.96 on Tuesday. (NYSE:BXP). Dnb Asset Management As holds 0.03% of its portfolio in Boston Properties, Inc. (NASDAQ:ALNY) for 45,390 shares. Dodge And Cox accumulated 9.14 million shares.

Alnylam Pharmaceuticals, Inc. has a 1-year low of $39.66 and a 1-year high of $147.63. (NASDAQ:ALNY) rating on Thursday, June 22. The biggest holder now is Dr. John M. Maraganore, PhD who owns 151,297 shares (0.15% of those outstanding), whilst Dr. Phillip A. Sharp, PhD holds 140,795 (0.14% of shares outstanding) and Barry E. Greene holds 100,428 (0.10% of shares outstanding). Rgm Capital Llc who had been investing in Cornerstone Ondemand Inc for a number of months, seems to be bullish on the $2.30 billion market cap company. (NYSE:BXP) rating on Monday, September 4. Ubs Asset Management Americas invested 0.15% of its portfolio in Alnylam Pharmaceuticals, Inc. Prudential Fincl has invested 0% of its portfolio in Alnylam Pharmaceuticals, Inc. Leerink Swann maintained Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY). Kornitzer Capital Mngmt Ks holds 0.33% or 162,835 shares in its portfolio.

Investors sentiment decreased to 1.91 in 2017 Q3. Its down 0.39, from 1.21 in 2017Q2. The stock was sold at an average price of $135.89, for a total value of $4,076,700.00. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company's stock worth $203,000 after buying an additional 167 shares during the period. State Street stated it has 0% in The Community Financial Corporation (NASDAQ:TCFC). Knott David M holds 0.01% or 110 shares in its portfolio. Shine Inv Advisory Inc has 0.01% invested in Westinghouse Air Brake Technologies Corporation (NYSE:WAB). Alnylam Pharmaceuticals reported sales of $17.45 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 54.2%. The shares of the corporation went down by -7.54% during the previous month. State Of Wisconsin Investment Board holds 16,294 shares. 172,596 were reported by Sei Co. Alliancebernstein L.P. now owns 47,873 shares of the biopharmaceutical company's stock valued at $3,818,000 after acquiring an additional 398 shares during the period. Profund Advisors Limited Co reported 0.03% stake. Piper Jaffray Companies restated a "buy" rating and set a $182.00 target price on shares of Alnylam Pharmaceuticals in a research report on Friday, November 17th. 4,018 were reported by Clearbridge Invests Lc. The Delaware-based Ashford Capital Management Inc has invested 1.33% in the stock.